There's a case for applying laws against profiteering to the drug industry, Dr. Joshua Sharfstein tells CNBC. » Read More
Singapore has confirmed 41 cases of locally transmitted Zika virus infection, while ramping up health screenings and mosquito control efforts.
Alere fell 3 percent after it sued Abbott to compel it to get all antitrust approvals required to complete its $5.8 billion merger.
The Food and Drug Administration wants all U.S. blood banks to start screening for Zika virus.
Mylan is trying to win over critics by issuing coupons to help consumers pay for its high-priced EpiPen. Don't be fooled, says Vox writer Sarah Kliff.
Wall Street likes health care despite its vulnerability to political headwinds and underperformance this year.
Obamacare rates are 7 percent less in states with greater Medicaid eligibility, a new analysis says.
Mylan has raised the price of EpiPens more than 400 percent in recent years. The medicine inside costs $1.
CNBC's Jim Cramer fired back Thursday on comments from Mylan CEO Heather Bresch about pricing of the auto-injection device EpiPen.
Under pressure, Mylan plans to boost access to its EpiPen Auto-Injector by expanding existing programs for patients who are facing higher costs.
Pharmaceutical company Mylan has reduced the cost of EpiPens for some people — but at the end of the day, its CEO told CNBC she has a business to run.
Should you buy long-term-care insurance? That's the question for workers nearing retirement. The cost of coverage and care is rising.
Price increases on life-saving EpiPens have parents outraged — but the CEO of the company that makes them said no one's more frustrated than her.
Most HealthCare.gov customers could buy health plans for under $100 per month next year even if prices grew by 25 percent.
Mylan announced plans to boost access to its EpiPen Auto-Injector by expanding programs for patients who are facing higher out-of-pocket costs.
Heather Bresch is the daughter of a U.S. senator, incorporated her American company in the Netherlands and got an MBA she wasn't entitled to.
Nancy Retzlaff, has filed a federal complaint against Turing Pharmaceuticals, the New York Times reports.
Get the best of CNBC in your inbox